Various G q protein-coupled receptor agonists such as the ␣ 1 adrenoceptor agonist phenylephrine, angiotensin II, and endothelin-1 are potent hypertrophic factors. There is evidence of potential cross talk between these agents, particularly in terms of endothelin-1 as playing a central role in mediating the actions of other hypertrophic factors. Using cultured rat neonatal ventricular myocytes, we assessed the potential cross talk between these factors and sought to examine the potential underlying mechanisms. Twenty-four-hour exposure to either agent produced significant hypertrophy as determined by cell size and molecular markers. Although the hypertrophic effects of phenylephrine and angiotensin II were expectedly prevented by ␣ 1 and AT 1 receptor antagonists, respectively, these effects were also blocked by the ET A receptor antagonist BQ123 [cyclo(D-Asp-Pro-D-Val-Leu-D-Trp)] but not by the ET B antagonist BQ788 (N-cis-2,6-dimethylpiperidinocarbonyl-L-␥-methylleucyl-D-1-methoxycarbonyltryptophanyl-D-norleucine). Both phenylephrine and angiotensin II significantly increased protein expression of both endothelin receptor subtypes. Both phenylephrine and angiotensin II produced significant activation of p38 as well as extracellular signal-regulated protein kinase and c-Jun NH 2 -terminal kinase, although this was unaffected by endothelin receptor blockade. Further studies revealed that the effects of phenylephrine and angiotensin II were mediated by stimulated endothelin-1 production occurring via two separate mechanisms: angiotensin II by increasing the levels of the endothelin-1 precursor prepro endothelin-1 and phenylephrine by upregulating endothelin-converting enzyme 1. Our results indicate that the endothelin-1 system plays an obligatory role in the hypertrophic response to both phenylephrine and angiotensin II in cultured myocytes through a mechanism independent of mitogenactivated protein kinase activation.
Regulation of cardiomyocyte hypertrophy occurs via complex mechanisms but to a large degree involves receptormediated intracellular processes initiated by paracrine, autocrine, and hormonal factors (Oshima et al., 2002) . For example, one such group of hypertrophic agonists, including the ␣ 1 adrenergic agonist phenylephrine (PE), angiotensin II (AngII), and endothelin-1 (ET-1), bind to specific G q proteincoupled receptor to initiate the intracellular response (Dorn and Brown, 1999) . In cultured cardiac myocytes, activation of G protein-coupled receptors by PE, AngII, and ET-1 not only induces cardiac hypertrophy (Simpson et al., 1982; Dzau, 1988; Shubeita et al., 1990 ) but also up-regulates the activity of mitogen-activated protein kinases (MAPKs) (Clerk and Sugden, 2000; Molkentin and Dorn, 2001 ), a superfamily composed of three overall branches of the serine/threonine kinases extracellular signal-regulated protein kinase (ERK), c-Jun NH 2 -terminal kinase (JNK), and p38.
Recent evidence suggests cross talk between AngII and ET-1 (Mulder et al., 1997) . For example, AngII has been shown to stimulate the production of ET-1 in neonatal rat ventricular myocytes through a mechanism involving prepro ET-1 stimulation (Ito et al., 1993) . The potential role of the ET-1 system in regulating hypertrophic responses to AngII is of importance in terms of understanding the mechanistic basis for hypertrophic responses and also in terms of designing therapeutic strategies aimed at limiting the hypertrophic phenotype. However, it is not known whether ET-1 plays an obligatory role in the hypertrophic responses to other factors and whether there is reciprocity in cross talk between these agents. Accordingly, the present study was designed to address these questions as well as the potential underlying mechanisms. ET-1 has also been shown to activate ET A or ET B receptors on cardiomyocytes to induce cellular hypertrophy (Ito et al., 1993; Cullen et al., 2001 ), but there is no evidence to date whether the expression of ET A and ET B can be regulated by PE or AngII. Accordingly, we also sought to determine whether PE or AngII can directly modulate ET receptors in cultured cardiomyocytes.
Materials and Methods
Primary Neonatal Cardiac Myocytes Culture. Myocytes were prepared from the ventricles of 4-day-old Sprague-Dawley rats as described in detail previously . In brief, the ventricles were excised, washed, and cut into small pieces in 15 ml of Hanks' balanced salt solution (Invitrogen, Burlington, ON, Canada), and then digested in 60 ml of Hanks' balanced salt solution containing 800 U of collagenase (Worthington Biochemicals, Lakewood, NJ) per ventricle. The digestion was performed in a circulating water bath to keep the reaction temperature at 37°C. The digestion was terminated by adding the same volume of 20% fetal bovine serum. The cells were sorted by a cell strainer to remove undigested particles and then centrifuged at 600g for 5 min at 4°C. The cell pellet was resuspended in a plating medium containing 10% fetal bovine serum and 0.1 mM bromodeoxyuridine and was preplated in tissue culture flasks for two times of 20 min to reduce contaminating nonmyocytes, after which the cells were transferred into Primaria cell culture dishes (BD Biosciences Labware, Mississauga, ON, Canada) and cultured for 48 h. The medium was replaced with a serum-free maintenance medium and incubated for another 24 h before being used for study. Approximately 95% of cells prepared by this method demonstrated sarcomeric myosin heavy chain staining, indicating relatively low nonmyocyte contamination (Rajapurohitam et al., 2003) .
Experimental Design. Myocytes were treated with either PE (10 M), AngII (100 nM), or ET-1 (10 nM) for 24 h. For some experiments, the cells were first treated with the appropriate antagonist for 15 min before agonist addition. These included the ␣ 1 adrenoceptor antagonist prazosin (1M), the AT 1 antagonist [Sar
the AT 2 antagonist PD 123319 (1 M), the ET A antagonist BQ123 (100 nM), and the ET B antagonist BQ788 (1 M). In addition, the endothelin-converting enzyme-1 (ECE-1) inhibitor phosphoramidon (PPRD) (10 M) was used in some studies and added using a protocol identical to the receptor antagonists. All agents used were from Sigma Diagnostics Canada (Oakville, ON, Canada).
Cell Area Measurement. The cells were plated at a density of 1 ϫ 10 6 cells/6-cm dish to obtain individually plated cells. At the end of the treatment period, the cells were washed twice with PBS after which they were viewed using a Leica DMIL inverted microscope equipped with a Polaroid digital camera. Eight random photographs were taken from each sample and surface area from at least five cells from each photograph was determined in a blinded manner using Mocha software (SPSS Inc., Chicago, IL). Thus, surface area from at least 40 cells was averaged to obtain one "n" value.
RT Tables 1 and 2 , respectively. Western Blot Analysis. Cells were plated at a concentration of 6 ϫ 10 6 cells/6-cm dish. After washing twice with PBS, the cells were scraped into 100 l of lysis buffer (20 mM Tris, 150 mM NaCl, 1% Triton X-100, 10% glycerol, 2 mM EDTA, 2 mM EGTA, 50 mM NaF, 200 M Na 3 VO 4 , 10 mM Na 4 P 2 O 7 , 40 mM ␤-glycerophosphate, 10 g/ml leupeptin, 1 M pepstatin A, 1 mM phenylmethylsulfonyl fluoride, and 1 M colyculin A). The lysate was transferred to 1.5-ml Eppendorf tubes, homogenized, and then centrifuged at 10,000g for 5 min at 4°C. The supernatant was transferred to a fresh tube, and the protein concentration was assayed by Bradford protein assay kit (Bio-Rad, Mississauga, ON, Canada). Protein (30 g) was loaded in 10% SDS-polyacrylamide gel electrophoresis, and transferred to nylon membrane (Amersham Biosciences UK, Ltd., Little Chalfont, Buckinghamshire, UK). The membranes were blocked in 5% dry milk for 3 h, primary antibody for 2 h, secondary antibody for 1 h, and then detected by enhanced chemiluminescence reagent (Amersham Biosciences UK, Ltd.). ET A , ET B , and actin antibodies were from Chemicon International (Temecula, CA) and used at a 1:500 dilution except for actin, which was used at a dilution of 1:2000 dilution. Antibodies against pp44/42, ERK, pp38, p38, pJNK, and JNK were purchased from Cell Signaling Technology Inc. (Beverly, MA) and used at a 1:1000 dilution. Enzyme Immunometric Assay. Myocytes were plated at 3 ϫ 10 6 cells/3.5-cm dish. Big ET-1 and ET-1 protein levels in the culture media were measured using enzyme immunometric assay kits (Assay Design, Chicago, IL) according to the manufacturer's instructions. The cross-reactivity of rat big ET-1 antibody with either ET-1, ET-2, or ET-3 was Ͻ0.1%, whereas cross-reactivity of the ET-1 antibody with either ET-2 or ET-3 was 3.32 and Ͻ0.1%, respectively.
Statistical Analysis. All values in the figures and text are presented as mean Ϯ S.E.M. Sample size per experiment is indicated in the results. Data were analyzed by one-way analysis of variance with P Ͻ 0.05 considered to represent significant differences between groups.
Results

Effect of ET Receptor Blockade on the Hypertrophic
Effects of PE and AngII. As an initial assessment of the potential role of the ET system to the hypertrophic effects of other factors, we first determined whether blocking ET receptors can alter the response to either PE or AngII. As shown in Fig. 1 , both PE (A) and AngII (B) significantly increased cell surface area by approximately 40 and 50%, respectively. The ET A receptor antagonist BQ123 completely abrogated the hypertrophic response to both agents, whereas the ET B receptor antagonist BQ788 was without effect.
To further assess the nature of the hypertrophic phenotype in response to agonists, we determined the mRNA expression of two molecular hypertrophic markers, atrial natriuretic peptide (ANP) and myosin light chain-2 (MLC-2) by RT-PCR and real-time PCR (Fig. 2) . Both PE and AngII significantly increased expression of these two markers, which was prevented by the ET A receptor antagonist BQ123 and the ET B receptor antagonist BQ788.
Effect of ␣ 1 Adrenoceptor and AngII Receptor Blockade on ET-1-Induced Cardiac Hypertrophy. Studies were carried out, as summarized in Table 3 , to assess whether the hypertrophic effect of ET-1 can be modulated by blocking ␣ 1 or AngII receptors. However, neither the ␣ 1 adrenoceptor antagonist prazosin, the AT 1 receptor antagonist [Sar 1 -Ile 8 ]-angiotensin II, or the AT 2 receptor antagonist PD 123319 had any effect on ET-1-induced cardiac hypertrophy. Furthermore, prazosin has no effect on AngII-induced hypertrophy, whereas neither of the AngII antagonists influenced PE-induced hypertrophy (Table 3) .
Effect of PE and AngII on ET A and ET B Receptor Protein Expression in Cardiac Myocytes. Figure 3 summarizes our results aimed at assessing whether ET receptor expression is affected by either PE or AngII. Both the ET A and the ET B receptor were significantly increased after 24-h treatment with either agent. We next wished to determine whether the up-regulation of ET receptors occurred via direct effects or secondary mechanisms, possibly via ET-1 up-regulation. Initial studies determined the effect of PPRD, which inhibits the ECE-1 that converts big ET-1 to ET-1. As shown in Fig. 3 , PPRD, which had no effect of its own completely prevented the up-regulation of the ET A receptor by both PE (A) as well as AngII (B). In contrast, PPRD directly increased ET B expression on its own and has no effect on ET B upregulation produced by either PE (Fig. 3C) or AngII (Fig. 3D) .
Effect of PPRD on PE and AngII-Induced Hypertrophy. As shown in Fig. 4 , the hypertrophic effect of both PE and AngII was completely prevented by PPRD, which on its own was without effect, thus suggesting that endogenous ET-1 mediates the hypertrophic effect of these two agents.
Comparative Effects of PE and AngII on ECE-1 and ET-1 Expression. The ability of PPRD to prevent the upregulation of the ET A receptor by both PE and AngII prompted us to examine whether ECE-1 could be directly modified by either agent as a potential explanation for ET A up-regulation. As shown in Fig. 5 , PE significantly increased ECE-1 expression 3-fold, whereas AngII was completely without effect. In contrast, however, AngII increased expression of prepro ET-1 directly, although prepro ET-1 expression was unaffected by PE. Moreover, the magnitude of prepro ET-1 up-regulation was virtually identical to the effect of PE on ECE-1.
Together, the results suggest an ability of PE and AngII to stimulate ET-1 production via two distinct mechanisms. To demonstrate this directly, we next studied the relative ability of each agent to augment synthesis of big ET-1, the immediate ET-1 precursor, as well as ET-1 itself by determining the levels of these peptides in culture medium after agonist addition. As shown in Fig. 6 , both PE and AngII significantly increased ET-1 production, whereas, in contrast, only AngII significantly increased the levels of big ET-1. The increased ET-1 production induced by PE was abolished by the ␣ 1 antagonist prazosin, whereas the increased ET-1 and big ET-1 production induced by AngII was inhibited by the AT 1 blocker [Sar 1 -Ile 8 ]-AngII and to a lesser degree by the AT 2 antagonist PD 123319. The ability of both AngII receptor antagonists to exert inhibitory effects was surprising, although this may infer a role for multiple receptor subtypes in mediating the effect of AngII on the ET-1 system.
Effect of Treatments on MAPK Activity. All three hypertrophic factors used in this study activate MAPK pathways in cardiac myocytes, and we therefore explored whether the prevention of cardiac hypertrophy by BQ123 is related to MAPK activity. As shown in Fig. 7 , PE significantly increased MAPK activity as evidenced by increased phosphorylation of p44/42 (ERK), p38, and JNK, whereas AngII has little effect. Moreover, PE-and AngII-induced MAPK activation was unaffected by either the ET A receptor antagonist BQ123 or the ET B receptor antagonist BQ788.
Discussion
ET-1 has initially been identified as a potent vasoconstricting factor produced by vascular endothelial cells, although it has also been demonstrated to be synthesized by cardiac cells (Sakai et al., 1996) . ET-1 acts via two G protein-coupled receptors (ET A and ET B ), although the ET A receptor represents 90% of endothelin receptors in cardiomyocytes (Fareh et al., 1996; Sakai et al., 1996) . ET-1 has been implicated in the pathophysiology of myocardial infarction and congestive heart failure (Ezra et al., 1989; Stewart et al., 1991; Grover et al., 1993) , the latter role likely attributable to its potent hypertrophic actions, thus potentially contributing to the myocardial remodeling process (Yorikane et al., 1993) . ET-1 and ET receptor expression can be increased by numerous Endothelin System in Cardiomyocyte Hypertrophy (Rubanyi and Polokoff, 1994) . AngII has been shown to up-regulate prepro ET-1 mRNA level in cultured cardiac myocytes (Ito et al., 1993) , potentially suggesting that stimulation of ET-1 synthesis mediates at least some of the effects of this hormone. To assess and expand this hypothesis, we studied the effect of two hypertrophic factors, AngII and the ␣ 1 adrenoceptor agonist PE, on cardiomyocyte hypertrophy and carried out an in-depth assessment to determine whether the ET system mediates these hypertrophic responses. Our data strongly suggest an important role for ET-1 and its receptors, but especially the ET A receptor in mediating the actions of both AngII and PE through a mechanism involving increased synthesis of ET-1. However, our study also reveals that the ability of these agents to increase ET-1 production occurs via different mechanisms.
A role for ET-1 mediating the hypertrophy produced by PE and AngII is borne out by various lines of evidence that can be summarized as follows. The increased cell area produced by both agents was completely blocked by the ET A receptor antagonist BQ123. We also attempted to document changes in molecular markers. PE and AngII not only increased the cell area but also the expression of both ANP and MLC-2 (Chien et al., 1991) . Moreover, both ET receptor antagonists blocked the up-regulation of ANP and MLC-2 induced by PE and AngII. The ability of the ET B blocker BQ788 to inhibit both ANP and MLC up-regulation by PE and AngII, while leaving increased cell area produced by both agents unaffected was surprising but may reflect the complexity of the hypertrophic process and ET signaling. Indeed, ET B represents only 10% of the ET receptor in cardiomyocyte (Fareh et al., 1996) , and it is possible that blocking of ET B is sufficient to inhibit the hypertrophic marker expression but not the overall hypertrophic effect. The ability of PE and AngII to up-regulate expression of both cardiac ET receptors ET A and ET B further supports the notion that the ET system could potentially mediate the effects of these agents. To assess whether PE and AngII directly up-regulate these receptors or whether this reflects a secondary response via endogenous ET-1, we determined the effect of PPRD, an agent that inhibits the enzyme ECE-1 that catalyzes the conversion of big ET-1 to ET-1. PPRD blocked the up-regulation of the ET A receptor by both PE and AngII, whereas it had no effect on ET B up-regulation by these agents. Moreover, PPRD surprisingly directly up-regulated ET B expression in the absence of any other intervention. The studies with PPRD further support the concept of ET A receptor mediation of hypertrophic responses because the agent blocked the increased cell area produced by both PE and AngII.
Studies with PPRD further suggested that endogenous ET-1 mediates the hypertrophic response to both PE and AngII. We sought to explore this concept by direct measurements of ET-1 and components of the ET-1 synthesis pathways. Indeed, both PE and AngII increased release of ET-1 from cardiac cells, although subsequent analysis revealed that this occurs via different mechanisms. Accordingly, AngII, but not PE increased big ET-1 levels. Moreover, PE, but not AngII stimulated ECE-1 expression, as reported previously by others (Kaburagi et al., 1999) , whereas conversely, only AngII increased prepro ET-1 expression. The integration of these findings into our working hypothesis is summarized below.
As summarized in Fig. 7 , we also studied the potential cell signaling mechanisms in mediating the hypertrophic responses by concentrating on the MAPK family. MAPK, but particularly ERK1/2, is generally associated with cell growth and is strongly activated by ET-1, PE, and AngII (Clerk et al., 1994; Miyata and Haneda, 1994) , although it should be noted that ERK1/2 inhibition has been shown not to reduce the hypertrophic phenotype in various experimental settings (Clerk et al., 1998; Ono et al., 2000) . In addition, both JNK and p38 can also be activated by PE and AngII in cardiac myocytes, although these are more markedly activated by cytotoxic cellular stresses such as osmotic or oxidative stress jpet.aspetjournals.org (Bogoyevitch et al., 1995; Clerk et al., 1998) . Our results showed that the early stimulation of all three components of the MAPK family by PE and AngII was unaffected by ET receptor blockade. Thus, ET receptor blockade inhibits the hypertrophic response but leaves the MAPK activation unaffected. This finding is not completely surprising because 10-min treatment would not be expected to be sufficient time for either PE or AngII to increase synthesis of the ET-1 peptide. Overall, this finding suggests, but does not necessarily prove, that the obligatory role of ET-1 in mediating the hypertrophic response to either PE or AngII can be dissociated from MAPK activation.
Conclusion
Our findings strongly support the hypothesis that ET-1 mediates the hypertrophic response to both PE and AngII and that both agents increase ET-1 synthesis by the cardiac cell. However, two recent studies using either pharmacological ET A receptor antagonism (De Smet et al., 2003) or cardiomyocyte-specific ET A knockout mice (Kedzierski et al., Fig. 4 . Blockade of PE-and AngII-induced hypertrophy by the ECE-1 inhibitor PPRD. Cells were pretreated with PPRD for 15 min after which they were treated with PE or AngII for 24 h. The cell area data showed PPRD completely blocked hypertrophic response to both PE (A) and AngII (B). ‫,ء‬ P Ͻ 0.05 versus control (n ϭ 5).
Fig. 5.
Comparative effects of PE and AngII on ECE-1 and prepro ET-1 expression. The myocytes were treated with PE or AngII for 24 h. ECE and prepro ET-1 expression were measured by real time PCR, and the data were normalized by 18S RNA and compared with control. PE significantly induced ECE expression in 24 h (n ϭ 6; ‫,ءءء‬ P Ͻ 0.001) but had no effect on prepro ET-1. In contrast, AngII has no effect on ECE-1 expression but significantly increased expression of prepro ET-1 by 3-fold (n ϭ 6; †, P Ͻ 0.05). 6 . Effect of PE and AngII on ET-1 and big ET-1 levels in myocyte culture medium. Cells were first treated with the appropriate antagonist after which PE or AngII was added for 24 h. Protein levels of ET-1 and big ET-1 were measured in the medium using enzyme immunometric assay kit. Both PE and AngII significantly enhanced ET-1 levels (A), although only AngII increased big ET-1 levels (B). ‫,ء‬ P Ͻ 0.05 versus control (n ϭ 6).
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2003) failed to demonstrate a pivotal role for this receptor against AngII-induced hypertrophy. We are unable at present to explain the divergent results but this may represent the type of experimental model. Moreover, as suggested by these authors, it is possible under chronic in vivo conditions other mechanisms are activated to compensate for ET A inhibition such as the up-regulation of other receptor subtypes. In view of the potential therapeutic relevance of this Fig. 7 . Representative Western blots and quantitative assessment of MAPK levels in response to agonists. Cells were treated with PE or AngII for 10 min after preincubated with ET receptor antagonists BQ123 or BQ788 for 15 min. Numbers indicate the following treatment groups: 1, control; 2, PE; 3, PE ϩ BQ123; 4, PE ϩ BQ788; 5, AngII; 6, AngII ϩ BQ123; and 7, AngII ϩ BQ788. Note that MAPK activation occurred in response to PE and AngII but was unaffected by ET-1 receptor blockade (n ϭ 3). Fig. 8 . Proposed mechanism for ET-1 as a mediator of the hypertrophic response to PE and AngII in cardiomyocytes. PE stimulates the production of ET-1 by increasing ECE-1 expression, resulting in increased ET-1 production. In contrast, AngII increases ET-1 production by stimulating prepro ET-1 expression. ET-1 then exerts its hypertrophic effect by acting primarily on ET A receptors and increasing their expression. The ability of PPRD to up-regulate ET B receptor expression suggests a possible direct effect of the agent or by disinhibiting an inhibitory influence of endogenous ET-1. phenomenon further work is necessary to fully understand the importance of these findings particularly under in vivo conditions.
Our hypothesis regarding the nature of this activation based on our systematic evaluation of the ET system in response to the two agonists in cultured myocytes is summarized in Fig. 8 . According to this scheme, both PE and AngII increase the production of ET-1, although via separate mechanism: AngII by increasing expression of prepro ET-1 and PE by activating ECE-1, thus resulting in increased conversion of big ET-1 to ET-1 with the latter acting on the ET A receptor to produce the hypertrophic response. Hypertrophy is thus prevented by PPRD because this agent blocks the conversion of big ET-1 to ET-1. The ability of PPRD to up-regulate the ET B receptor was surprising but may suggest that endogenous ET-1 serves as an inhibitory regulator of this receptor, which is then reversed by ECE-1 inhibition, or it may reflect a direct stimulatory effect of PPRD on the ET B receptor.
